2-Decarboxy-2-hydroxymethyl-9-deoxy-9-methylene-5,6-didehydro-PGF1 compounds
DESCRIPTION 
     CROSS REFERENCE TO RELATED APPLICATIONS 
     The present application is a divisional application of U.S. Ser. No. 035,144, filed May 1, 1979, now pending. 
    
    
     BACKGROUND OF THE INVENTION 
     The present invention particularly relates to novel 2-decarboxy-2-hydroxymethyl-9-deoxy-9-methylene-5,6-didehydro-PGF 1  compounds and methods for their preparation and pharmacological use. 
     The essential material constituting the disclosure of the preparation and pharmacological use of the compounds of the present invention is incorporated here by reference from U.S. Ser. No. 035,144 and U.S. Pat. No. 4,060,534. The latter patent describes certain 9-deoxy-9-methylene-PGF-type compounds which are cis isomers of the novel compounds disclosed herein. 
     PRIOR ART 
     Known in the art are trans-5,6-didehydro PG 1  compounds and 9-deoxy-9-methylene PGF compounds. Trans-5,6-didehydro prostaglandins are described in U.S. Pat. Nos. 3,759,978, 3,823,180, 3,832,379, and 3,821,291. 
     SUMMARY OF THE INVENTION 
     The present invention particularly provides: 
     a prostaglandin analog of formula VI ##STR1## 
     wherein Y 1  is trans-CH═CH--, --C.tbd.C--, --CH 2  CH 2  --, or cis-CH═CH--; 
     wherein M 1  is α-R 5  :β-OH or α-OH:β-R 5 , wherein R 5  is hydrogen or methyl; 
     wherein L 1  is α-R 3  :β-R 4 , α-R 4  :β-R 3 , or a mixture of α-R 3  :β-R 4  and α-R 4  :β-R 3  wherein R 3  and R 4  are hydrogen, methyl, or fluoro, being the same or different, with the proviso that one of R 3  and R 4  is fluoro only when the other is hydrogen or fluoro; 
     wherein g is 3, 4, or 5; and 
     wherein m is one to 5 inclusive. 
    
    
     DESCRIPTION OF THE PREFERRED EMBODIMENTS 
     The present invention particularly relates to the following specific embodiment: 
     2-decarboxy-2-hydroxymethyl-5,6-trans-didehydro-9-deoxy-9-methylene-16,16-dimethyl-PGF 1 .